Novavax Reports Vaccine 90% Effective; Supply Questions Remain
Novavax Reports Vaccine 90% Effective; Supply Questions Remain Voice of America Another highly effective vaccine is poised to join the fight against COVID-19. But its impact may be blunted by supply issues. The manufacturer expected to produce the bulk of the doses is in India, where the government has banned vaccine exports. Biotech company Novavax announced Monday that its vaccine was 100% effective in preventing severe cases of COVID-19 and 90% effective in preventing any form of the disease in a clinical trial in the United States and Mexico. The company has an agreement to sell 350 milli...